2025国家医保谈判启动，港股通创新药ETF（520880）跌逾2%创3个月新低！基金经理：当下或是高胜率配置时点

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced a decline of over 2%, reaching a three-month low, amidst a backdrop of significant capital inflow and ongoing negotiations regarding the national medical insurance directory and commercial insurance for innovative drugs [1][2]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) covers 37 innovative drug companies, with over 30 experiencing declines in early trading, including major drops of over 6% for companies like InnoCare Pharma and Innovent Biologics [1]. - The ETF has seen a year-to-date increase of 108.14%, outperforming other innovative drug indices, and has the largest scale and best liquidity among similar ETFs, with a fund size of 1.806 billion and an average daily trading volume of 493 million since its inception [3]. Group 2: Policy Developments - The introduction of a "commercial insurance innovative drug directory" mechanism marks a shift in China's medical insurance system towards multi-layered protection, potentially alleviating the financial burden of high-value innovative drugs through commercial insurance channels [1]. - The recent "14th Five-Year Plan" emphasizes the promotion of biomanufacturing as a new economic growth point, indicating a supportive policy environment for the pharmaceutical sector [2]. Group 3: Investment Insights - The fund manager of the ETF suggests that despite recent market disturbances, the policy foundation is solid, and the performance trend is positive, indicating that this may be a high-probability investment period for the pharmaceutical sector, particularly innovative drugs [2].